2 documents found, page 1 of 1
Fidaxomicin for Clostridiodes difficile infection in inflammatory bowel disease...
Noviello, D.; Chaparro, M.; Viganò, C.; Blesl, A.; Barberio, B.; Yanai, H.; Macaluso, F.; Iglesias, R. Ferreiro; Bezzio, C.; Zilli, A.; Molnár, T.Inflammatory bowel disease (IBD) patients with Clostridiodes difficile Infection (CDI) are at increased risk of disease exacerbations, therapy escalation, colectomy, and mortality. Data on fidaxomicin use in IBD patients with CDI are very limited. We aimed to assess the effectiveness and safety of fidaxomicin for CDI and its impact on IBD outcomes in a large retrospective multicenter cohort study
Pre-operative exposure to tofacitinib is as safe as biologics in patients with ...
Dragoni, G.; Innocenti, T.; Amiot, A.; Castiglione, F.; Melotti, L.; Festa, S.; Savarino, E. V.; Truyens, M.; Argyriou, K.; Noviello, D.; Molnar, T.Patients with ulcerative colitis (UC) receiving immunomodulators are at substantial risk of colectomy. Since robust evidence regarding the post-operative outcomes of patients treated with anti-JAKs in the pre-operative phase is lacking, we aimed to assess the risk of complications of tofacitinib exposure prior to colectomy in comparison with anti-TNFs, vedolizumab, and ustekinumab.